Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005778725> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2005778725 endingPage "599" @default.
- W2005778725 startingPage "588" @default.
- W2005778725 abstract "Objective To compare glycemic control with add-on insulin glargine versus pioglitazone treatment in patients with type 2 diabetes. Methods This 48-week, multicenter, parallel-group, open-label study randomized 389 adults with poorly controlled type 2 diabetes (glycated hemoglobin A1c [A1C], 8.0% to 12.0%), despite ≥3 months of sulfonylurea or metformin monotherapy, to receive add-on therapy with insulin glargine or pioglitazone. Outcomes included A1C change from baseline to end point (primary), percentage of patients achieving A1C levels ≤7.0%, and changes from baseline in fasting plasma glucose, body mass index, weight, and serum lipids. The safety analysis included incidence of adverse events and rates of hypoglycemia. Results At end point, insulin glargine yielded a significantly greater reduction in A1C in comparison with pioglitazone (-2.48% versus -1.86%, respectively; 95% confidence interval, -0.93 to -0.31; P = .0001, 48-week modified intent-to-treat population). Insulin glargine also yielded significantly greater reductions in fasting plasma glucose at all time points (end point difference, -34.9 mg/ dL; 95% confidence interval, -47.6 to -22.2; P<.0001). In comparison with pioglitazone, insulin glargine resulted in a lower overall incidence of possibly related treatmentemergent adverse events (12.0% versus 20.7%) and fewer study discontinuations (2.2% versus 9.1%), but a higher rate (per patient-year) of confirmed clinically relevant hypoglycemic episodes (blood glucose <70 mg/dL and all severe hypoglycemia) (4.97 versus 1.04; P<.0001) and severe hypoglycemia (0.07 versus 0.01; P = .0309). Weight and body mass index changes were similar between the 2 treatment groups. Conclusion The addition of insulin glargine early in the diabetes treatment paradigm in patients for whom sulfonylurea or metformin monotherapy had failed resulted in significantly greater improvements in glycemic control in comparison with the addition of pioglitazone. Although severe hypoglycemia was more frequent in patients with insulin glargine therapy, hypoglycemic events occurred in <5% of patients in the insulin glargine treatment group. (Endocr Pract. 2010;16:588-599)" @default.
- W2005778725 created "2016-06-24" @default.
- W2005778725 creator A5040283884 @default.
- W2005778725 creator A5057048949 @default.
- W2005778725 creator A5064307950 @default.
- W2005778725 date "2010-07-01" @default.
- W2005778725 modified "2023-10-16" @default.
- W2005778725 title "Improved Glycemic Control with Insulin Glargine Versus Pioglitazone as Add-On Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus" @default.
- W2005778725 cites W1791343978 @default.
- W2005778725 cites W1975588287 @default.
- W2005778725 cites W1996441843 @default.
- W2005778725 cites W2088970881 @default.
- W2005778725 cites W2090824142 @default.
- W2005778725 cites W2105407506 @default.
- W2005778725 cites W2122130517 @default.
- W2005778725 cites W2123946565 @default.
- W2005778725 cites W2146901298 @default.
- W2005778725 cites W2626017884 @default.
- W2005778725 cites W4251418881 @default.
- W2005778725 doi "https://doi.org/10.4158/ep09281.or" @default.
- W2005778725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20350924" @default.
- W2005778725 hasPublicationYear "2010" @default.
- W2005778725 type Work @default.
- W2005778725 sameAs 2005778725 @default.
- W2005778725 citedByCount "30" @default.
- W2005778725 countsByYear W20057787252012 @default.
- W2005778725 countsByYear W20057787252013 @default.
- W2005778725 countsByYear W20057787252014 @default.
- W2005778725 countsByYear W20057787252015 @default.
- W2005778725 countsByYear W20057787252017 @default.
- W2005778725 countsByYear W20057787252019 @default.
- W2005778725 crossrefType "journal-article" @default.
- W2005778725 hasAuthorship W2005778725A5040283884 @default.
- W2005778725 hasAuthorship W2005778725A5057048949 @default.
- W2005778725 hasAuthorship W2005778725A5064307950 @default.
- W2005778725 hasConcept C126322002 @default.
- W2005778725 hasConcept C134018914 @default.
- W2005778725 hasConcept C168563851 @default.
- W2005778725 hasConcept C197934379 @default.
- W2005778725 hasConcept C203092338 @default.
- W2005778725 hasConcept C2777180221 @default.
- W2005778725 hasConcept C2777538456 @default.
- W2005778725 hasConcept C2778384471 @default.
- W2005778725 hasConcept C2778854520 @default.
- W2005778725 hasConcept C2779306644 @default.
- W2005778725 hasConcept C2779920387 @default.
- W2005778725 hasConcept C2780221984 @default.
- W2005778725 hasConcept C2780323712 @default.
- W2005778725 hasConcept C2780473172 @default.
- W2005778725 hasConcept C2780668416 @default.
- W2005778725 hasConcept C2908647359 @default.
- W2005778725 hasConcept C2910068830 @default.
- W2005778725 hasConcept C555293320 @default.
- W2005778725 hasConcept C71924100 @default.
- W2005778725 hasConcept C90924648 @default.
- W2005778725 hasConcept C99454951 @default.
- W2005778725 hasConceptScore W2005778725C126322002 @default.
- W2005778725 hasConceptScore W2005778725C134018914 @default.
- W2005778725 hasConceptScore W2005778725C168563851 @default.
- W2005778725 hasConceptScore W2005778725C197934379 @default.
- W2005778725 hasConceptScore W2005778725C203092338 @default.
- W2005778725 hasConceptScore W2005778725C2777180221 @default.
- W2005778725 hasConceptScore W2005778725C2777538456 @default.
- W2005778725 hasConceptScore W2005778725C2778384471 @default.
- W2005778725 hasConceptScore W2005778725C2778854520 @default.
- W2005778725 hasConceptScore W2005778725C2779306644 @default.
- W2005778725 hasConceptScore W2005778725C2779920387 @default.
- W2005778725 hasConceptScore W2005778725C2780221984 @default.
- W2005778725 hasConceptScore W2005778725C2780323712 @default.
- W2005778725 hasConceptScore W2005778725C2780473172 @default.
- W2005778725 hasConceptScore W2005778725C2780668416 @default.
- W2005778725 hasConceptScore W2005778725C2908647359 @default.
- W2005778725 hasConceptScore W2005778725C2910068830 @default.
- W2005778725 hasConceptScore W2005778725C555293320 @default.
- W2005778725 hasConceptScore W2005778725C71924100 @default.
- W2005778725 hasConceptScore W2005778725C90924648 @default.
- W2005778725 hasConceptScore W2005778725C99454951 @default.
- W2005778725 hasIssue "4" @default.
- W2005778725 hasLocation W20057787251 @default.
- W2005778725 hasOpenAccess W2005778725 @default.
- W2005778725 hasPrimaryLocation W20057787251 @default.
- W2005778725 hasRelatedWork W2063008961 @default.
- W2005778725 hasRelatedWork W2070740840 @default.
- W2005778725 hasRelatedWork W2083441169 @default.
- W2005778725 hasRelatedWork W2095717568 @default.
- W2005778725 hasRelatedWork W2211602199 @default.
- W2005778725 hasRelatedWork W2460294411 @default.
- W2005778725 hasRelatedWork W2624999659 @default.
- W2005778725 hasRelatedWork W2952077955 @default.
- W2005778725 hasRelatedWork W3118157210 @default.
- W2005778725 hasRelatedWork W4309193185 @default.
- W2005778725 hasVolume "16" @default.
- W2005778725 isParatext "false" @default.
- W2005778725 isRetracted "false" @default.
- W2005778725 magId "2005778725" @default.
- W2005778725 workType "article" @default.